Revance to Participate in Upcoming Investor Conferences

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (RVNC) today announced that the company will be participating in the following investor conferences.

Cowen 44th Annual Healthcare Conference
Chief Executive Officer, Mark Foley and Chief Financial Officer, Tobin Schilke are scheduled to participate in a fireside chat on Tuesday, March 5, 2024, at 12:50p.m. EST, in Boston, Massachusetts.

Barclays Global Healthcare Conference 2024
Chief Executive Officer, Mark Foley, is scheduled to participate in a fireside chat on Tuesday, March 12, 2024, at 9:30a.m. EST, in Miami, Florida.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.

About Revance

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY (daxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY in China.

Revance is headquartered in Nashville, Tenn., with additional office locations in Newark and Irvine, Calif. Learn more at Revance.com, RevanceAesthetics.com, DAXXIFY.com, HCP.DaxxifyTherapy.com, or connect with us on LinkedIn.

“Revance”, the Revance logo, and DAXXIFY are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240221269040/en/

Investors
Revance Therapeutics, Inc.:
Jessica Serra, 510-279-6886
[email protected]
or
Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620
[email protected]

Media
Revance Therapeutics, Inc.:
Cathryn Castaldo, 615-245-7567
[email protected]

Source: Revance Therapeutics, Inc.

You May Also Be Interested In

• Taiho Oncology and Taiho Pharmaceutical to Present Data from AZTOUND Trial Evaluating Oral Azacitidine and Cedazuridine in Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia at the 68th Amer
• RevMedica Appoints Former Boston Scientific Executive Mike Jones as Chief Executive Officer
• Corvias Highlights How Existing Authorities and Partnerships Can Deliver Solutions for Military Installation Challenges